Hemostatic Disorders  >>  carfilzomib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

22 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carfilzomib / Generic mfg.
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Checkmark P2 data
Jul 2012 - Jul 2012: P2 data
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data at ASH
More
Completed
2
312
US, Canada
carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Amgen
Multiple Myeloma
11/10
10/12
NCT00721734: Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Checkmark P2 data-ASCO
May 2012 - May 2012: P2 data-ASCO
Checkmark P2 data at ASH
Nov 2011 - Nov 2011: P2 data at ASH
Completed
2
50
US
Carfilzomib, PR-171, Kyprolis®
Amgen
Multiple Myeloma, Renal Insufficiency
11/12
11/12
NCT00530816: Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Checkmark P2 data-ASCO
May 2012 - May 2012: P2 data-ASCO
Checkmark P2 data in MM
May 2012 - May 2012: P2 data in MM
Checkmark P2 data at ASH
More
Completed
2
164
US, Canada
carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Amgen
Multiple Myeloma
01/13
07/13
NCT00461045: Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Completed
2
15
US
MRZ 0.5 mg/m^2, Marizomib, NPI-0052
Celgene
Multiple Myeloma
09/14
10/14
CARAMEL 2, NCT01812720: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Withdrawn
2
0
US
carfilzomib, Kyprolis, PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, laboratory biomarker analysis
Mayo Clinic, National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
09/14
10/14
NCT02235740: A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Terminated
2
1
US
Afuresertib, Carfilzomib
Novartis, Amgen
Cancer
10/15
10/15
NCT02020941: Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Terminated
2
10
US
carfilzomib, Kyprolis, PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, laboratory biomarker analysis
Attaya Suvannasankha, National Cancer Institute (NCI)
Refractory Multiple Myeloma
01/16
04/16
NCT01351623: Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Completed
2
44
US
Carfilzomib
Memorial Sloan Kettering Cancer Center, Amgen
Multiple Myeloma
01/16
01/16
NCT01775553: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Completed
2
13
US
Carfilzomib, High Dose Carfilzomib
Ajai Chari, Amgen
Relapse Multiple Myeloma, Refractory Multiple Myeloma
05/16
05/16
NCT01470196: Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Completed
2
31
US
Dexamethasone, Decadron, Carfilzomib, PR-171, Rituximab, Rituxan
Dana-Farber Cancer Institute, Amgen
Waldenstrom's Macroglobulinemia
09/16
09/16
NCT00884312: A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

Completed
2
101
US, Canada
Carfilzomib, PR-171, PR171, Kyprolis®
Amgen
Multiple Myeloma, Solid Tumors
05/17
05/17
NCT02114502: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Withdrawn
2
0
US
Carfilzomib, SAHA, Vorinostat, Suberoylanilide Hydroxamic Acid, MSK-390, Zolinza, Gemcitabine, Gemcitabine Hydrochloride, Gemzar, Busulfan, Busulfex, Myleran, Melphalan, Alkeran, Stem Cell Transplant (SCT), Palifermin, Kepivance, Dexamethasone, Decadron, Caphosol, Glutamine, Enterex, Glutapak-10, NutreStore, Resource, GlutaSolve, Sympt-X G.I., Sympt-X, Pyridoxine
M.D. Anderson Cancer Center
Myeloma
09/18
 
PANORAMA-5, NCT02756663: Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Withdrawn
2
0
US, Canada, Europe, RoW
panobinostat (capsules), PAN, LBH589, carfilzomib (infusion), CFZ, dexamethasone (tablets), Dex
Novartis Pharmaceuticals
Multiple Myeloma
02/21
02/21
NCT01029054: Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Checkmark P1/2 data
Jun 2012 - Jun 2012: P1/2 data
Checkmark P1/2 data at ASH 2011
Nov 2011 - Nov 2011: P1/2 data at ASH 2011
Completed
1b/2
53
US
carfilzomib, lenalidomide plus dexamethasone
University of Michigan Rogel Cancer Center, Onyx Therapeutics, Inc., Celgene
Multiple Myeloma
12/11
07/15
NCT00531284: Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma

Checkmark P1/2 data (Solid Tumors, Multiple Myeloma, or Lymphoma)
Aug 2013 - Aug 2013: P1/2 data (Solid Tumors, Multiple Myeloma, or Lymphoma)
Checkmark P1/2 data at ASH
Nov 2011 - Nov 2011: P1/2 data at ASH
Completed
1b/2
184
US
Carfilzomib, Kyprolis, Dexamethasone
Amgen
Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Multiple Myeloma, Lymphoma
10/14
05/17
CARMYSAP, NCT01279694: Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma

Checkmark P1/2 data-ASCO
Jun 2012 - Jun 2012: P1/2 data-ASCO
Completed
1/2
72
Europe
Carfilzomib, Melphalan, alkéran, Prednisone
Nantes University Hospital
Myeloma
02/14
02/14
NCT01658904 / 2005-005964-10: Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Terminated
1/2
3
US
Carfilzomib, Melphalan, Filgrastim
National Cancer Institute (NCI)
Multiple Myeloma, Leukemia, Plasma Cell
02/14
04/14
NCT01057225: Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Checkmark P3 data: ASH (MM)
Nov 2013 - Nov 2013: P3 data: ASH (MM)
Checkmark P1/2 data-ASCO
Jun 2012 - Jun 2012: P1/2 data-ASCO
Checkmark P1/2 data EHA 2012
More
Completed
1/2
64
US
carfilzomib, PR-171, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Enduxan, thalidomide, alpha-phthalimidoglutarimide, Contergan, Kevadon, Synovir, THAL, Thalomid, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, Decaspray, DM, DXM
Mayo Clinic
Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
03/14
09/17
NCT01365559: Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Checkmark P2 data
Aug 2012 - Aug 2012: P2 data
Checkmark P1/2 data-ASCO
Jun 2012 - Jun 2012: P1/2 data-ASCO
Checkmark P1/2 data at ASH
More
Completed
1/2
39
US
Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.
Oncotherapeutics, Amgen
Multiple Myeloma
06/14
03/16
NCT01690143: Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Completed
1/2
45
US
Carfilzomib, Melphalan
University of Alabama at Birmingham, Amgen
Multiple Myeloma
11/17
11/17
NCT01246063: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
1/2
40
US
carfilzomib, Kyprolis, CFZ, pegylated liposomal doxorubicin (PLD), DOXIL, Dexamethasone, Decadron
Washington University School of Medicine
Multiple Myeloma
12/17
03/18
NCT02802163: Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Withdrawn
1/2
0
NA
Panobinostat, LBH589, deacetylase inhibitor (DACi), Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone, Decadron, corticosteroid
H. Lee Moffitt Cancer Center and Research Institute, Novartis, Amgen
Multiple Myeloma
09/20
12/20

Download Options